New drug BL-M24D1 enters early human testing for Hard-to-Treat cancers
NCT ID NCT07279428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called BL-M24D1 in 33 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and get a first look at whether the drug shrinks tumors. Participants receive the drug by IV every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M24D1
- What this could lead to
- If it works, this could point toward a new treatment option for advanced gastrointestinal and other solid tumors.
- What could go wrong
- This is an early Phase I trial with only 33 participants, focused on safety and dosing. It is too small and early to know if it will be effective or have manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?